Squamous Differentiation in pT1 Low-Grade Bladder Urothelial Carcinoma is Associated with High Risk of Recurrence

Wanqing Wei  
Tianjin Medical University

Jianwei Zhang  
Tianjin Medical University

Keruo Wang  
Tianjin Medical University

Shunlin Xia  
Tianjin Medical University

Zhiquan Shang  
Tianjin Medical University

Gang Li  
Tianjin Medical University

Yuanjie Niu (✉ niuyuanjie2020@163.com)  
Tianjin Medical University  https://orcid.org/0000-0002-0863-0061

Research article

Keywords: Squamous Differentiation, Urothelial Carcinoma, Recurrence, Bladder Cancer, Invasive Recurrence

DOI: https://doi.org/10.21203/rs.3.rs-378427/v1

License: ☛ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background** A large number of studies have confirmed that squamous differentiation is closely related to the prognosis of bladder cancer, and studies also showed that it is an independent predictor for the prognosis of such disease. However, the role of squamous differentiation in pT1 low-grade bladder cancer (LGBC) has not been reported yet. This study mainly intends to explore the clinical significance of squamous differentiation in pT1 LGBC.

**Methods** The clinicopathological data of 582 patients with pT1 LGBC from April 2007 to December 2018 were retrospectively analyzed, including 51 cases pathologically diagnosed as pT1 LGBC with squamous differentiation, and 531 cases as pT1 LGBC without squamous differentiation. The clinicopathological characteristics and prognosis of patients in the two groups were compared.

**Results** 51 cases (8.7%) were pathologically diagnosed as pT1 LGBC with squamous differentiation. As compared with non-squamous differentiation, squamous differentiation was closely related to the age of patients (P=0.009) and postoperative recurrence (P<0.001). Further studies on the pT1 LGBC recurrence group showed that the patients in the squamous differentiation group were more prone to multiple recurrences (P=0.033) and invasive recurrence (P<0.001) after surgery. The Kaplan-Meier analysis indicated that pT1 LGBC patients with squamous differentiation had shorter recurrence-free survival (RFS) time. The Cox proportional hazard analysis confirmed that squamous differentiation was an independent predictor of RFS time in patients with pT1 LGBC.

**Conclusions** Squamous differentiation is closely related to postoperative recurrence of pT1 LGBC, especially multiple recurrences and invasive recurrence after surgery. Squamous differentiation is an independent predictor of the RFS time in patients with pT1 LGBC.

**Background**

The incidence of bladder tumors ranks first among urinary tract tumors, which seriously threatens the health of people all over the world [1,2]. The majority of bladder tumors are urothelial carcinomas [3], and tissue-type variations with squamous differentiation have been found in about 20%-40% of cases [4-7]. The kind of tissue-type variation is closely related to high invasiveness and easy recurrence of tumor [8]. A large number of studies have clarified that squamous differentiation is an important prognostic factor of urothelial carcinoma [9-13], but there is no relevant research on squamous differentiation in patients with pT1 LGBC. Our study intends to clarify the role of squamous differentiation in pT1 LGBC, and to our knowledge, this is the first study focusing on the clinical significance of squamous differentiation in pT1 LGBC.

**Methods**

**Patients and specimens**
We retrospectively analyzed the clinical and pathological data of 582 patients pathologically diagnosed as pT1 LGBC in our hospital from April 2007 to December 2018. Patients with the history of urothelial carcinoma or associated urothelial carcinoma were excluded. The patients were divided into two groups based on whether they had squamous differentiation according to the pathological diagnosis. Surgical treatment and intravesical chemotherapy were performed to all patients. The indicators for evaluating the disease progression and prognosis of the patients included age, gender, recurrence, lymphatic vascular invasion and squamous differentiation. Cystoscopy was conducted regularly after the operation. Pathological biopsy was performed if abnormalities were found, and the recurrence was judged based on the results of the biopsy: the urothelial carcinoma in the pathological report of biopsy is defined as recurrence, e.g. the second pathological grade higher than the first pathological grade is defined as invasive recurrence. RFS (recurrence free survival) is defined as the time after patients’ operation and before the first recurrence of bladder cancer. The pathological classification is based on the WHO 2004 version of the malignant degree classification system of bladder urothelial carcinoma.

Pathology

All surgical specimens were completely presented to a pathologist, and the pathologist reviewed each pathological section one by one, in order to fully evaluate the clinical stage and pathological grade of tumors. Then two pathologists selected three representative sections of each specimen for independent review, to finally determine the pathological results and squamous differentiation. Routine hematoxylin-eosin (H&E) staining was used to diagnose the presence of lymphatic vascular invasion and squamous differentiation. The presence of intercellular bridges or keratinization was a sign of squamous differentiation.

Statistical methods

The study data was statistically analyzed by R (Version 3.6.3). Chi-square test and T-test were used to analyze the relationship between squamous differentiation and clinicopathological characteristics. The Kaplan-Meier method was used to analyze the overall survival time and the RFS time, and the difference analysis was calculated by log-rank test. The Cox proportional hazard analysis was used for the univariate and multivariate analysis. P-value was bidirectional, and when P<0.05, the difference is deemed statistically significant.

Results

Clinical characteristics

Clinical and pathological characteristics were presented in Table 1. There were a total of 582 patients pathologically diagnosed as pT1 LGBC, with the average age of 62.9, including 466 males and 116 females, with the ratio of male to female of 4:1. 51 patients (8.7%) were pathologically diagnosed as pT1 LGBC with squamous differentiation. Squamous differentiation had no significant relationship with the gender (P=0.159) or lymphatic vascular invasion (P=0.286), but it was correlated with the age (P=0.009).
Elderly patients were more prone to squamous differentiation. As compared with patients of the group without squamous differentiation, patients of the group with squamous differentiation were more prone to tumor recurrence after surgery (35% vs 11%, P < 0.001).

During the follow-up period, a total of 78 pT1 LGBC patients experienced postoperative recurrence. Detailed clinical and pathological characteristics were shown in Table 2. As compared with the group without squamous differentiation, the group with squamous differentiation was more prone to multiple recurrences (56% vs 28%, P = 0.033) and invasive recurrence (44% vs 18%, P < 0.001) after surgery.

**Oncological outcome**

The median follow-up time was 58 months (6-136 months). About 4.8% (28 cases) patients died during the follow-up period, and about 13.4% (78 cases) patients had tumor recurrence after surgery. The five-year overall survival rate of patients with pT1 LGBC was 97.8%, that of the group of tumor patients with squamous differentiation was 92.2%, and that of the group of tumor patients without squamous differentiation was 98.3%. There was no significant difference in the overall survival rate between the two groups (P = 0.065, Fig. 1). However, as compared with the group without squamous differentiation, the group with squamous differentiation had a shorter RFS time (P < 0.001, Fig. 2) and a shorter median recurrence time (30 vs 37 months). The univariate COX analysis showed squamous differentiation (HR, 2.834; 95% CI, 1.690-4.754; P = 0.001, Table 3). Lymphovascular invasion (HR, 1.79; 95% CI, 1.137-2.817; P = 0.012, Table 3) was an important factor to predict the RFS time of patients with pT1 LGBC. The univariate and multivariate Cox analyses confirmed that squamous differentiation (HR, 2.969; 95% CI, 1.765-4.999; P < 0.001; Table 3) was an independent predictor of RFS time, but age and gender were not important factors affecting the RFS time.

**Pathology**

Histological variations in squamous differentiation were observed by pathologists in all the 51 cases. When an obvious intercellular bridge and/or keratinization were observed in tumor cells, it was considered that the tumor cells had squamous differentiation. Its main histological characteristics are: 1. Clusters or nests of large and middle nuclear infiltrating tumor cells, often with nucleoli; 2. Unclear separation of cytoplasmic amphiphilic or eosinophilic cytoplasmic background. HE stained sections were used to confirm the presence of lymphatic vascular infiltration.

**Discussion**

Mazzucchelli and Bacchi first reported squamous differentiation as an indicator of the severity and prognosis of urothelial carcinoma [14]. Subsequently, in studies on bladder urothelial carcinoma, squamous differentiation has attracted researchers’ more and more attention. Recently, several studies have shown that squamous differentiation is an independent prognostic factor of urothelial carcinoma [15-17], consistent with the results of the study of Li and Yu, who demonstrated by univariate and multivariate analyses that squamous differentiation was an independent prognostic factor of pT1
bladder urothelial carcinoma, and was associated with high risk of recurrence and poor prognosis [10]. However, a large number of literatures have proved that squamous differentiation is only one of the factors affecting the prognosis. For example, Xu et al. analyzed 869 patients with TURBT and found that squamous differentiation was only an independent predictor of postoperative recurrence, which was closely related to tumor recurrence and RFS [17]. Minato et al. retrospectively analyzed the clinical and pathological data of 80 patients who had undergone radical bladder cancer resection, and the results showed that squamous differentiation was an independent predictor of the overall survival and RFS time [18].

There is no relevant research report on the role of squamous differentiation in pT1 LGBC. It was found in our study that elderly patients with bladder cancer (P=0.159) were more prone to squamous differentiation. As compared with the group without squamous differentiation, the group of pT1 LGBC patients with squamous differentiation was more prone to tumor recurrence after surgery (P<0.001). There was no statistical difference between squamous differentiation and the gender of patients (P=0.159) or lymphatic vascular invasion (P=0.286). Further studies of the clinical and pathological data of 78 patients with recurrence showed that the group of patients with squamous differentiation was more prone to multiple recurrences (56% VS 28%, P=0.033) and invasive recurrence (44% VS 18%, P<0.001) after surgery. Therefore, squamous differentiation was closely related to postoperative recurrence of patients with pT1 LGBC, and was an important factor affecting postoperative recurrence of patients.

The study of Li et al. confirmed that squamous differentiation is an important indicator to predict the sensitivity of chemotherapy in the bladder, which is closely related to the insensitivity and poor prognosis of chemotherapy [19]. Lin et al. conducted a meta-analysis of a total of 13,284 patients with LGBC from 19 studies, and the results showed that squamous differentiation is not an independent predictor of the prognosis of bladder cancer, but is associated with poor clinicopathological characteristics, high risk of recurrence and poor prognosis [20]. The results of our study support the above conclusions. The five-year overall survival rates of the groups of pT1 LGBC patients with squamous differentiation and without squamous differentiation were 92.2% and 98.3% respectively. There was no significant difference in the overall survival rate between the two groups (P=0.065, Fig. 1). However, as compared with the group without squamous differentiation, the group with squamous differentiation had a shorter RFS time (P<0.001, Fig. 2) and a median recurrence time (30 VS 37 months). The results of the univariate COX analysis showed squamous differentiation (HR, 2.834; 95%CI, 1.690-4.754; P=0.001; Table 3) is an important factor affecting the RSF time of patients with pT1 LGBC. The Cox proportional hazard model was used for the multi-factor analysis, further confirming the squamous differentiation (HR, 2.969; 95% CI, 1.765-4.999; P<0.001; Table 3) is an independent predictor of RFS time.

Sanderson et al. conducted a follow-up analysis of 1069 bladder cancer patients who had undergone radical bladder cancer resection, and the results showed that the median recurrence time was 39.6 (4.8-112 months) months [21]. Mariappan et al. conducted a 25-year follow-up of 115 patients with bladder cancer, and the results showed that the majority of patients with bladder urothelial carcinoma recurring within 5 years after surgery, and 12% of them had disease progression [22]. Our follow-up results are
consistent with the results of the study of Sanderson and Mariappan. Analysis of the follow-up results of 78 patients showed that 64 (82%) patients with pT1 LGBC recurrence within 5 years after surgery. The squamous differentiation group had a shorter median recurrence time (30 vs. 37 months), but 18% patients with pT1 LGBC still had tumor recurrence after 5 years. This prompts urologists that patients with pT1 LGBC may need a longer period of close follow-up after surgery.

**Conclusions**

This is the first study focusing on the clinical significance of squamous differentiation in patients with pT1 LGBC. Squamous differentiation is closely related to postoperative recurrence of pT1 LGBC, especially multiple recurrences and invasive recurrence after surgery. Squamous differentiation is an independent predictor of the RFS time in patients with pT1 LGBC.

**Abbreviations**

LGBC: Low-grade bladder cancer

TURBT: Transurethral bladder tumor resection

RFS: Recurrence free survival

SDN: Squamous differentiation-negative

SDP: Squamous differentiation-positive

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Tianjin Medical University. All procedures followed were in accordance with the Helsinki Declaration of 1964 and later versions. Each patient was fully informed of the investigational nature of this study and provided their written, informed consent.

**Consent for publication**

All authors have reviewed the final version of the manuscript and agree with its content and submission.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**
The authors declare that they have no conflict of interest.

**Funding**

This work was supported by National Natural Science Foundation of China (grants 82072851, 81872100 and 81772756), Natural Science Foundation of Tianjin (18PTLCSY00030 and 19JCYBJC24900). The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Author information**

Wanqing Wei, Jianwei Zhang and Keruo Wang contributed equally to this work.

**Affiliations**

Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.

Wanqing Wei, Keruo Wang, Zhiqun Shang, Gang Li, Yuanjie Niu

Department of Pediatric Surgery, Huai'an Maternal and Children Health Hospital, Huai'an 223002, China.

Wanqing Wei, Shunlin Xia

Tianjin Baodi Hospital, Baodi Clinical College of Tianjin Medical University, Tianjin, 301800, China

Jianwei Zhang

**Authors’ contributions**

WQW, ZQS, GL and YJN designed the study; JWZ, SLX and KRW collected the study material and patients’ information; WQW, JWZ, SLX, KRW, ZQS, GL and YJN assembled and analyzed the data; WQW, JWZ, SLX and KRW drafted the manuscript; all authors read and approved the final manuscript.

**Corresponding authors**

Correspondence to Yuanjie Niu or Gang Li.

**Acknowledgements**

The authors thank the patients who participated in the study, the study-site personnel, and the members of the data and safety monitoring committee.

**References**
1. Black PC, Brown GA, Dinney CPN (2009) The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 27 (1):3-7. doi:10.1016/j.urolonc.2007.07.010

2. Li G, Yu J, Song H, Zhu S, Sun L, Shang Z, Niu Y (2017) Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. BMC Cancer 17 (1):530. doi:10.1186/s12885-017-3520-1

3. Liu Y, Bui MM, Xu B (2017) Urothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis. Cancer Control 24 (1):78-82

4. Lopez-Beltran A, Cheng L (2006) Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 37 (11):1371-1388

5. Lopez-Beltran A, Requena MJ, Alvarez-Kindelan J, Quintero A, Blanca A, Montironi R (2007) Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. J Clin Pathol 60 (3):332-335

6. Martin JE, Jenkins BJ, Zuk RJ, Blandy JP, Baithun SI (1989) Clinical importance of squamous metaplasia in invasive transitional cell carcinoma of the bladder. J Clin Pathol 42 (3):250-253

7. Mazzucchelli R, Scarpelli M, Galosi AB, Di Primio R, Lopez-Beltran A, Cheng L, Montironi R (2014) Pathology of upper tract urothelial carcinoma with emphasis on staging. Int J Immunopathol Pharmacol 27 (4):509-516

8. Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Capogrosso P, Shariat SF, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R (2016) Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. Eur J Surg Oncol 42 (5):735-743. doi:10.1016/j.ejso.2016.02.011

9. Sefik E, Celik S, Basmaci I, Yarımoglu S, Bozkurt IH, Yonguc T, Gunlusoy B (2018) Effect of variant histology presence and squamous differentiation on oncological results and patient's survival after radical cystectomy. Arch Ital Urol Androl 90 (3):172-175. doi:10.4081/aiua.2018.3.172

10. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP (2006) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12 (22):6663-6676

11. Kim SP, Frank I, Cheville JC, Thompson RH, Weight CJ, Thapa P, Boorjian SA (2012) The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol 188 (2):405-409. doi:10.1016/j.juro.2012.04.020

12. Li G, Hu J, Niu Y (2018) Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. Oncotarget 9 (1):217-223. doi:10.18632/oncotarget.18563

13. Lin X, Deng T, Wu S, Lin SX, Wang D, Wu C-L (2020) The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis. World J Urol 38 (2):323-333. doi:10.1007/s00345-019-02771-1

14. Makise N, Morikawa T, Kawai T, Nakagawa T, Kume H, Homma Y, Fukayama M (2015) Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma. Int J Clin Exp Pathol 8 (6):7203-7209
15. Mazzucchelli L, Bacchi M, Studer UE, Markwalder R, Sonntag RW, Kraft R (1994) Invasion depth is the most important prognostic factor for transitional-cell carcinoma in a prospective trial of radical cystectomy and adjuvant chemotherapy. Int J Cancer 57 (1):15-20

16. Minato A, Fujimoto N, Kubo T (2017) Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder. Clin Genitourin Cancer 15 (6):e1063-e1067. doi:10.1016/j.clgc.2017.07.008

17. Minato A, Noguchi H, Tomisaki I, Fukuda A, Kubo T, Nakayama T, Fujimoto N (2018) Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder. Cancer Control 25 (1):1073274818800269. doi:10.1177/1073274818800269

18. Mitra AP, Bartsch CC, Bartsch G, Miranda G, Skinner EC, Daneshmand S (2014) Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol 32 (2):117-127. doi:10.1016/j.urolonc.2012.08.017

19. Tang Q, Xiong G, Li X, Fang D, Xi C, Zhang L, Yang K, Yao L, Zhang C, Yu W, He Q, Gong K, He Z, Zhou L (2016) The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol 34 (6):871-877. doi:10.1007/s00345-015-1715-0

20. Xu H, Xie L, Liu X, Zhang Y, Shen Z, Chen T, Qiu X, Sha N, Xing C, Wu Z, Hu H, Wu C (2017) Impact of squamous and/or glandular differentiation on recurrence and progression following transurethral resection for non-muscle invasive urothelial carcinoma of bladder. Oncol Lett 14 (3):3522-3528. doi:10.3892/ol.2017.6581

21. Gulmann C, Paner GP, Parakh RS, Hansel DE, Shen SS, Ro JY, Annaiah C, Lopez-Beltran A, Rao P, Arora K, Cho Y, Herrera-Hernandez L, Alsabeh R, Amin MB (2013) Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol 44 (2):164-172. doi:10.1016/j.humpath.2012.05.018

22. Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN, Grignon DJ, Idrees MT, Emerson RE, Zhou X-J, Zhang S, Baldridge LA, Hahn NM, Wang M, Koch MO, Cheng L (2013) Novel markers of squamous differentiation in the urinary bladder. Hum Pathol 44 (10):1989-1997. doi:10.1016/j.humpath.2013.04.005

Tables

Table 1 Association of squamous differentiation with clinical and pathological characteristics.
| Characteristic                              | Total  | SDN   | SDP   | p value |
|--------------------------------------------|--------|-------|-------|---------|
| Cases, n (%)                               | 582(100) | 531(91) | 51(9) |         |
| Mean age (range), years                    | 62.9-14-95 | 62.5-14-90 | 67.3-37-95 | 0.009  |
| Gender, n (%)                              | 466(80) | 429(81) | 37(73) | 0.159   |
| Male                                       | 116(20) | 102(19) | 14(27) |         |
| Female                                     |        |       |       |         |
| Male:Female                                | 4:1    | 4.2:1 | 2.6:1 |         |
| Lymphovascular invasion, n (%)             | 407(70) | 368(69) | 39(76) | 0.286   |
| NO                                         | 175(30) | 163(31) | 12(24) |         |
| YES                                        |        |       |       |         |
| Intravesical recurrence, n (%)             | 504(87) | 471(89) | 33(65) | <0.001  |
| NO                                         | 78(13)  | 60(11) | 18(35) |         |
| YES                                        |        |       |       |         |

Table 2 Correlation of squamous differentiation with clinical and pathological characteristics in patients experienced postoperative recurrence.

| Characteristic                              | Total  | SDN   | SDP   | p value |
|--------------------------------------------|--------|-------|-------|---------|
| Cases, n (%)                               | 78(100) | 60(64) | 18(23) |         |
| invasive recurrence, n (%)                 |        |       |       | <0.001  |
| Yes                                        | 19(24)  | 11(18) | 8(44)  |         |
| No                                         | 59(76)  | 49(82) | 10(56) |         |
| Number of recurrence, n (%)                |        |       |       | 0.033   |
| ≥2                                         | 27(35)  | 17(28) | 10(56) |         |
| =1                                         | 51(65)  | 43(72) | 8(44)  |         |

Table 3 Univariate and multivariate Cox regression analyses predicting recurrence-free survival.
| Variable                          | Univariate analysis |                      | Multivariate analysis |                      |
|----------------------------------|---------------------|----------------------|-----------------------|----------------------|
|                                  | HR                  | 95% CI               | p value               | HR                  | 95% CI               | p value               |
| Age                              | 1.001               | 0.982-1.019          | 0.942                 | 0.998               | 0.981-1.017          | 0.908                 |
| Gender                           | 1.321               | 0.729-2.395          | 0.361                 | 1.442               | 0.793-2.623          | 0.231                 |
| Lymphovascular invasion         | 1.79                | 1.137-2.817          | 0.012                 | 1.836               | 1.166-2.891          | 0.009                 |
| Squamous differentiation         | 2.834               | 1.690-4.754          | 0.001                 | 2.969               | 1.765-4.996          | <0.001                |

**Figures**
Figure 1

Kaplan–Meier curve of the cancer-specific survival rates for the squamous differentiation-negative and squamous differentiation-positive in the subgroup of high-grade ($p = 0.065$). SDN: squamous differentiation-negative; SDP: squamous differentiation-positive.
Figure 2

Kaplan–Meier curve of the recurrence-free survival rates for the squamous differentiation-negative and squamous differentiation-positive (p<0.001). SDN: squamous differentiation-negative; SDP: squamous differentiation-positive.